Asthma Clinical Trials

• Participant must be aged 18 to 75 years of age.

• Documented diagnosis of asthma at least 12 months prior to Screening.

• Participants must be on maintenance asthma medications, for at least 3 months prior to screening: inhaled corticosteroid (ICS) in combination with long-acting beta agonist (LABA), or as part of an approved triple therapy for asthma (ICS/LABA/long-acting muscarinic antagonist \[LAMA\]).

• Participant has an ACQ-6 score ≥1.5 at Screening Visit.

• Participant has FEV1 of ≥50% to 90%, inclusive, of predicted normal value at Screening Visit 1.

• Evidence of asthma as documented by reversibility in FEV1 of ≥12% and ≥200 mL over the pre-salbutamol FEV1 at Screening Visit.